DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161506

A prospective study, to determine adverse effects of anti-retroviral agents in rural tertiary care teaching hospital

Swapnil Chudaman Jaykare, Jyoti Ramchandra Patil, Vijay Motiram Motghare, Sudhir Laxmanrao Padwal, Vinod Shivajirao Deshmukh, Harshal Nutanrao Pise

Abstract


Background: Acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV). Objective of this study was to evaluate the adverse drug reaction profile of anti-retroviral drugs in HIV patients in terms of causality, severity and preventability.

Methods: Patients newly started on ART were followed prospectively for a period of initial six months and were interviewed in person during their routine follow-up or visit following development of any ADRs. ADRs were screened clinically and investigated accordingly for causality, severity and preventability.

Results: Out of 59 cases, zidovudine+lamivudine+nevirapine (ZLN) was the most commonly used ART regimen. A total 122 ADRs involving various systems were observed in these patients; majority being related to gastrointestinal system (54.10%). Most of these ADRs were observed in the ZLN regimen followed by the stavudine+lamivudine+nevirapine (SLN) regimen. On causality assessment in ZLN regimen, 74.58% of ADRs were possible, while 25.42% were probable. Severity assessment showed that most of the ADR were mild whereas on preventability assessment it was observed that most of the ADRs were not-preventable.

Conclusions: Antiretroviral drugs are not solely responsible for the ADRs due to these medications; various co-morbid and predisposing conditions share the responsibility. An efficient pharmacovigilance is imperative by means of improving ADR reporting and monitoring, in order to improve compliance and acceptability of ART.


Keywords


ADRs, AIDS, Antiretroviral therapy, Causality, Pharmacovigilance, Preventability, Severity

Full Text:

PDF

References


Weiss RA. How does HIV cause AIDS? Science 1993;260:1273-79.

Kallings LO. The first postmodern pandemic: 25 years of HIV/ AIDS. J Intern Med. 2008;263:218-43.

Jacob IS, Singh A, Suryawanshi SN, Gautam V. In-silico inhibitor designing for HIV-1 integrase in human immunodeficiency virus. J Nat Sc Biol Med. 2011;2:64-5.

Jaykare SC, Motghare VM, Padwal SL, Pise HN, Deshpande RP. Antiretroviral therapy- newer drugs on the anvil. Indian Journal of Medical Specialities. 2013;4:47-54.

Cooper CL, Breau C, Laroche A, Lee C, Garber G. Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection. HIV Med. 2006;7:32-7.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.

Hartwig S, Siegel J, Schneider P. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm.1992;27:538.

American society of health-system pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Health-Syst Pharm. 1995;52:417-9.

Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170:229-38.

Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-30.

Duval X, Journot V, Leport C, Chene G, Dupon M, Cuzin L, et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis. 2004;39:248-55.

Annual Report 2010-11. National aids control organization. Available at http://www.nacoonline.org/upload/REPORTS/NACO%20Annual%20Report%202010-11.pdf.

Modayil RR, Harugeri A, Parthasarathi G, Ramesh M, Prasad R, Naik V, et al. Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiol Drug Saf. 2010;19:247-55.

Nagpal M, Tayal V, Kumar S, Gupta U. Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study. Indian J Med Sci. 2010;64:245-52.

Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol. 2008;74:234-7.

O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-14.

Singh H, Kachhap VK, Kumar BN, Nayak K. Nevirapine induced stevens-johnson syndrome in an HIV infected patient. Indian J Pharmacol. 2011;43:84-6.

Eluwa GI, Badru T, Akpoigbe K. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clinical Pharmacology. 2012;12:7.